替吉奥或紫杉醇联合顺铂治疗中晚期非小细胞肺癌的疗效比较

Comparison of the curative effect of S-1 or paclitaxel combined with cisplatin in the treatment of moderate and advanced non small cell lung cancer

目的比较替吉奥或紫杉醇联合顺铂治疗中晚期非小细胞肺癌(NSCLC)的疗效。方法确诊为中晚期NSCLC并接受含铂两药化疗的81例随机分成替吉奥联合顺铂组(简称替吉奥组,37例)和紫杉醇联合顺铂组(简称紫杉醇组,44例),分别接受替吉奥联合顺铂化疗和紫杉醇联合顺铂化疗。比较两组患者的生存时间、毒副作用的发生率以及近期治疗效果。结果两组的近期疗效差异有统计学意义(Hc=4.338,P<0.05),替吉奥组的临床获益率明显高于紫杉醇组(86.5%vs 68.2%,P<0.05),白细胞下降、消化道不良反应、脱发和神经毒性毒副反应的比例低于紫杉醇组,差异有统计学意义(P<0.01或0.05)。结论替吉奥联合顺铂治疗中晚期NSCLC患者中,在临床获益率和降低化疗引起的毒副作用方面优于紫杉醇联合顺铂的方案。

Objective To compare the curative effect of S-1 or paclitaxel combined with cisplatin in the treatment of moderate and advanced non small cell lung cancer. Methods 81 patients with moderate and advanced non small cell lung cancer were randomly divided into S-1 combined with cisplatin group （Group S-1, n=37） and paclitaxel combined with cisplatin group （Group Paclitaxel, n=44）, receiving chemotherapy with S-1 combined with cisplatin and with paclitaxel combined with cisplatin respectively. The survival time, the incidelace of side effects and the recent therapeutic effect of the two groups were compared. Results There was significant statistical difference in recent therapeutic effect between the two groups （Hc=4.338, P〈0.05）. The clinical benefit rate of Group S-1 was significantly higher than that of Group Paclitaxel （86.5% vs 68.2%, P〈0.05）; the occurrence rate of WBC decline, gastrointestinal adverse reactions, alopecia and neurotoxic side effects of Group S-1 were lower than those of Group Paclitaxel, and the difference was statistically significant （P〈0.05 or 0.01）. Conclusion S-1 combined with cisplatin was superior to paclitaxel combined with cisplatin in the treatment of moderate and advanced non small cell lung cancer in terms of clinical benefit rate and reduction of toxic and side effects caused by chemotherapy.